Lineage Cell Therapeutics, Inc. operates as a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, neurological conditions associated with demyelination, and aiding the body in detecting and combating cancer. The company's programs are based on two core proprietary technology platforms: cell replacement and cell and drug delivery. Its cell replacement platform creates new cells and tissues with its pluripotent and progenitor cell technologies. The company's cell and drug delivery programs are based upon its proprietary HyStem cell and drug delivery matrix technology. It engages in the research and development of regenerative medicine or therapeutic products for advancement in the field of oncology, orthopedics, retinal and neurological diseases and disorders, blood and vascular system diseases and disorders, blood plasma volume expansion, diagnostic products for the early detection of cancer and hydrogel products that may be used in surgery and products for human embryonic stem cell research. The company was founded by Judith Segall, Hal Sternberg, Paul E. Segall and Harold D. Waitz on November 30, 1990 and is headquartered in Carlsbad, CA.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
77
Frequently Asked Questions
What is Market Cap of Lineage Cell Therapeutics Inc?
Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. Lineage Cell Therapeutics Inc market cap is $306M.
What is the 52-week high for Lineage Cell Therapeutics Inc?
52 week high is the highest price of a stock in the past 52 weeks, or one year. Lineage Cell Therapeutics Inc 52 week high is $1.42 as of September 16, 2025.
What is the 52-week low for Lineage Cell Therapeutics Inc?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Lineage Cell Therapeutics Inc 52 week low is $0.3651 as of September 16, 2025.
What is Lineage Cell Therapeutics Inc stock price today?
Lineage Cell Therapeutics Inc stock price today is $1.35.
What was Lineage Cell Therapeutics Inc stock price yesterday?
Lineage Cell Therapeutics Inc stock price yesterday was $1.34.
What is the PE ratio of Lineage Cell Therapeutics Inc?
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It’s calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company’s Market Cap by the Net Profit. Lineage Cell Therapeutics Inc’s P/E ratio is -7.34.
What is the Price-to-Book ratio of Lineage Cell Therapeutics Inc?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It’s calculated by dividing a company’s market capitalization by its book value. Lineage Cell Therapeutics Inc P/B ratio is 6.3243.
What is the 50-day moving average of Lineage Cell Therapeutics Inc?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. Lineage Cell Therapeutics Inc 50-day moving average is $1.10.
How many employess does Lineage Cell Therapeutics Inc has?